As such, the MET inhibitors plus immune checkpoint inhibitors (ICIs) strategy has been improving pancreatic cancer immunotherapeutic efficacy [50], evidencing potential crosstalk between c-MET inhibition and immune escape since PD-L1 expression positively correlates with METamp [51]. The gene discussed is MET; the disease is familial pancreatic carcinoma.